Suppr超能文献

调强放疗治疗复发性鼻咽癌的长期生存和晚期并发症。

Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.

机构信息

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.

出版信息

BMC Cancer. 2018 Nov 20;18(1):1139. doi: 10.1186/s12885-018-5055-5.

Abstract

BACKGROUND

To evaluate the effectiveness and toxicities of intensity-modulated radiotherapy (IMRT) for locally recurrent nasopharyngeal carcinoma (NPC).

METHODS

One hundred and eighty-four previously irradiated NPC patients with recurrent disease and re-irradiated by IMRT between February 2005 to May 2013 had been reviewed. The disease was re-staged I in 33, II in 27, III in 70 and IV in 54 patients. Seventy-five percent of the patients received cisplatin-based chemotherapy.

RESULTS

The median survival time was 33 months. The 3-year actuarial rates of local recurrence-free survival (LRFS), distant metastases-free survival (DMFS), and overall survival (OS) rates were 85.1, 91.1, and 46.0%, respectively. About 53% of the patients experienced Grade 3-4 late toxicities. Forty-four patients died of massive hemorrhage of the nasopharynx caused by radiation induced mucosal necrosis. Multivariate analysis indicated that chemotherapy and time interval between initial radiotherapy and re-irradiation were independent predictors for DMFS.

CONCLUSION

IMRT is an effective method for patients with locally recurrent NPC. Massive hemorrhage of the nasopharynx is the major sever late complication and also the leading cause of death. Early recurrence is negative factor for DMFS. Combination of chemotherapy can improve DMFS, but not for OS. Optimal salvage treatment strategies focusing on improvement of survival and minimization of late toxicities are warranted.

摘要

背景

评估调强放疗(IMRT)治疗局部复发性鼻咽癌(NPC)的有效性和毒性。

方法

回顾分析了 2005 年 2 月至 2013 年 5 月期间 184 例接受过调强放疗的局部复发 NPC 患者。33 例患者疾病分期为 I 期,27 例为 II 期,70 例为 III 期,54 例为 IV 期。75%的患者接受了顺铂为基础的化疗。

结果

中位生存时间为 33 个月。3 年局部无复发生存率(LRFS)、无远处转移生存率(DMFS)和总生存率(OS)的 actuarial 率分别为 85.1%、91.1%和 46.0%。约 53%的患者发生 3-4 级晚期毒性。44 例患者死于放射诱导的黏膜坏死引起的鼻咽大出血。多因素分析表明,化疗和初始放疗与再放疗之间的时间间隔是 DMFS 的独立预测因素。

结论

IMRT 是治疗局部复发性 NPC 的有效方法。鼻咽大出血是主要的严重迟发性并发症,也是导致死亡的主要原因。早期复发是 DMFS 的不利因素。联合化疗可以提高 DMFS,但不能提高 OS。需要制定以提高生存率和降低迟发性毒性为重点的最佳挽救治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec4a/6245884/f1161dd3fba3/12885_2018_5055_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验